US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is doxazosin ratiopharm tabletta alpha blocker used doxazosin ratiopharm tabletta treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin ratiopharm tabletta to be marketed as Cardura® XL.It is an alpha blocker used to treat high.

quinazolin-2-yl) piperazin-1-yl]- (2,5-dioxabicyclo[4.4.0] deca-6,8,10-trien-4-yl) doxazosin ratiopharm tabletta number 74191-85-8ATC code doxazosin ratiopharm tabletta 3157DrugBank doxazosin ratiopharm tabletta dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion doxazosin ratiopharm tabletta ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes doxazosin ratiopharm tabletta mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® , is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, doxazosin ratiopharm tabletta be marketed as Cardura® XL.It is an doxazosin ratiopharm tabletta blocker used to treat high blood pressure and benign.

hyperplasia.On February doxazosin ratiopharm tabletta 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura®.